---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Phase of product development"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Phase of product development. Topics: Summary: regulatory history and status; Regulatory status: Under review; NDA submitted April 2026 and accepted July 2026, with a PDUFA goal date of February 2027; NDA acceptance and PDUFA target action date, July 2026; Review timeline: 10-month review from submission; 11 further topics. 15 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Summary: regulatory history and status

- Current status: under FDA review. Apnimed submitted a New Drug Application (NDA) for Oxnimbi (AD109) through the section 505(b)(2) pathway in April 2026; the FDA accepted it for review in July 2026 and assigned a PDUFA goal date of February 28, 2027. The 10-Q states that the review cycle is targeted at 10 months from the April 2026 submission. No launch date has been stated.
- Designations: Fast Track designation for the treatment of OSA in May 2022.
- Proprietary name: Oxnimbi is a proposed name. The prospectus states that the FDA conditionally approved it in May 2025, reconfirmed it in June 2026, and that it is pending approval of the NDA; the third quarter 2026 release states that it remains subject to final FDA review and may change.
- Combination product requirement: as a fixed-dose combination, the product generally requires the sponsor to demonstrate the contribution of each component to the claimed effect and the safety and efficacy of the combination as a whole.
- FDA questions: at the pre-NDA meeting, the FDA gave feedback on the “clinical meaningfulness of certain endpoint results”, including the primary endpoint, and on the limitations of the patient-reported outcomes, and indicated that additional analyses and justification may be needed to show a clinically meaningful benefit. Apnimed states that it responded in the NDA. The third quarter 2026 Form 10-Q states that the FDA, in its acceptance letter and later communications, has raised questions regarding the adequacy of the NDA and has requested additional information, data, or analyses on the nonclinical, clinical, or CMC areas; its risk factors name the adequacy of stability data and the manufacturing process.
- Development completed: 13 phase 1, 2, and 3 trials, including two registrational phase 3 trials (LunAIRo in the United States and SynAIRgy in the United States and Canada).
- Earlier timing statements, now superseded: the May 2025 and July 2025 topline releases planned an NDA submission by early 2026; the March 2026 release expected submission in the second quarter of 2026; the April 2026 debt financing release expected it later that quarter; the May 2026 SynAIRgy publication release expected a PDUFA target action date in the first quarter of 2027, subject to FDA acceptance. The July 2026 acceptance, with a goal date of February 28, 2027, replaced these statements.

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm); [Apnimed third quarter results release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-reports-third-quarter-2026-financial-results-and); [Apnimed NDA acceptance release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-announces-fda-acceptance-new-drug-application-ad109); [Apnimed Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526462185/apmd-20260930.htm); [Apnimed SynAIRgy publication release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-announces-publication-its-phase-3-synairgy-trial-ad109); [Apnimed debt financing release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-secures-150-million-debt-financing-healthcare-royalty); [Apnimed SASS monetization release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-announces-strategic-monetization-shionogi-apnimed-sleep); [Apnimed LunAIRo topline release (2025)](https://apnimed.com/article/ad109toplinephase3results/); [Apnimed SynAIRgy topline release (2025)](https://apnimed.com/article/ad109phase3toplineresults/)

<a id="topic-2.1.1-2"></a>

### Regulatory status: Under review; NDA submitted April 2026 and accepted July 2026, with a PDUFA goal date of February 2027

> “Based on results from two registrational trials, we submitted a New Drug Application (NDA) for Oxnimbi to the U.S. Food and Drug Administration (FDA) in April 2026, which was accepted for review by the FDA in July 2026.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

> “Apnimed’s NDA for AD109 is under review by the FDA and was assigned a PDUFA goal date of February 28, 2027.”
> “The FDA has assigned a PDUFA goal date of February 28, 2027.”

Source: [Apnimed third quarter results release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-reports-third-quarter-2026-financial-results-and)

<a id="topic-2.1.1-3"></a>

### Launch

No evidence found.

<a id="topic-2.1.1-4"></a>

### NDA acceptance and PDUFA target action date, July 2026

> “The FDA assigned a PDUFA target action date of February 28, 2027”
> “Apnimed’s NDA for AD109 was assigned a PDUFA target action date of February 28, 2027.”

Source: [Apnimed NDA acceptance release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-announces-fda-acceptance-new-drug-application-ad109)

<a id="topic-2.1.1-5"></a>

### Review timeline: 10-month review from submission

> “The FDA review cycle is targeted to be 10 months from our NDA submission in April 2026”

Source: [Apnimed Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526462185/apmd-20260930.htm)

<a id="topic-2.1.1-6"></a>

### Regulatory pathway: section 505(b)(2) NDA

> “We submitted a NDA to seek FDA approval for Oxnimbi for OSA through the Section 505(b)(2) regulatory pathway.”

Source: [Apnimed Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526462185/apmd-20260930.htm)

<a id="topic-2.1.1-7"></a>

### Fixed-dose combination rule

> “Oxnimbi is a fixed-dose combination drug product. The development of combination therapies may be more complex than the development of single agent therapies and generally requires that sponsors demonstrate the contribution of each component to the claimed effect and the safety and efficacy of the combination as a whole.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.1-8"></a>

### Fast Track designation, May 2022

> “In May 2022, we received Fast Track designation for Oxnimbi for the treatment of OSA”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.1-9"></a>

### FDA pre-NDA feedback on the clinical meaningfulness of endpoint results

> “In connection with the FDA’s review of our top-line Phase 3 data, at the pre-NDA meeting, the FDA provided feedback about the clinical meaningfulness of certain endpoint results, including the primary endpoint and the limitations of the patient-reported outcomes (PROs). The FDA indicated that additional analyses and justification may be needed to support that the data demonstrates a clinically meaningful benefit for the treatment of OSA. We submitted information in response to this feedback in our NDA submission and plan to continue to address it and related requests as part of the FDA review process.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.1-10"></a>

### FDA questions raised in the acceptance letter and during review

> “In its acceptance letter and in any later communications during its review, the FDA has raised and may continue to raise questions or concerns regarding the adequacy of our NDA to support approval and has requested and may further request additional information, data or analyses to augment its review of the nonclinical, clinical or CMC areas of our application, which could require that we submit amendments to our NDA.”
> “the adequacy of our stability data and manufacturing process to support approval and commercial launch;”

Source: [Apnimed Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526462185/apmd-20260930.htm)

<a id="topic-2.1.1-11"></a>

### Clinical development completed: two phase 3 trials and 13 trials overall

> “We have conducted 13 Phase 1, 2 and 3 clinical trials that inform various aspects of the Oxnimbi program and have amassed clinical response and tolerability data for Oxnimbi across multiple completed clinical trials in OSA.”
> “LunAIRo was conducted in the United States and SynAIRgy was conducted in the United States and Canada. All previous trials of Oxnimbi were conducted in the United States.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.1-12"></a>

### PDUFA date expectation, May 2026, superseded in July 2026

> “Apnimed has submitted its NDA for AD109 to the FDA. Based on FDA’s prior feedback, Apnimed expects a potential Prescription Drug User Fee Act (PDUFA) target action date in the first quarter of 2027, subject to FDA acceptance of the NDA for review.”

Source: [Apnimed SynAIRgy publication release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-announces-publication-its-phase-3-synairgy-trial-ad109)

<a id="topic-2.1.1-13"></a>

### NDA submission timing, April 2026, superseded in April 2026

> “Apnimed previously reported positive results from the pivotal SynAIRgy and LunAIRo Phase 3 trials for AD109, which will support the planned submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration, expected later this quarter.”

Source: [Apnimed debt financing release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-secures-150-million-debt-financing-healthcare-royalty)

<a id="topic-2.1.1-14"></a>

### NDA submission timing, March 2026, superseded in April 2026

> “Transaction strengthens Apnimed’s balance sheet as the Company separately prepares to submit its NDA for AD109 in Obstructive Sleep Apnea, expected in the second quarter of 2026”

Source: [Apnimed SASS monetization release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-announces-strategic-monetization-shionogi-apnimed-sleep)

<a id="topic-2.1.1-15"></a>

### NDA submission timing, July 2025, superseded in March 2026

> “Apnimed plans to submit a New Drug Application for AD109 to the U.S. Food and Drug Administration (FDA) by early 2026”

Source: [Apnimed LunAIRo topline release (2025)](https://apnimed.com/article/ad109toplinephase3results/)

<a id="topic-2.1.1-16"></a>

### NDA submission timing, May 2025, superseded in March 2026

> “Apnimed plans to submit a New Drug Application (NDA) for AD109 to the U.S. Food and Drug Administration (FDA) by early 2026 for regulatory review.”

Source: [Apnimed SynAIRgy topline release (2025)](https://apnimed.com/article/ad109phase3toplineresults/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
